Markos N. Marangos

Patra, ESYE23, Greece

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 181 publications

When might we consider using the newer β-lactam agents as empirical therapy against presumed carbapenem-resistant gram-negative infections?

When might we consider using the newer β-lactam agents as empirical therapy against presumed carbapenem-resistant gram-negative infections?

Journal: JAC-antimicrobial resistance

Published: August 18, 2026

Candidemia in post-COVID era: increasing incidence of endemic fluconazole-resistant Candida parapsilosis and Candidozyma auris.

Candidemia in post-COVID era: increasing incidence of endemic fluconazole-resistant Candida parapsilosis and Candidozyma auris.

Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Published: May 21, 2026

Candidemia in Post-COVID Era: Increasing incidence of endemic fluconazole-resistant Candida parapsilosis and Candidozyma auris.

Candidemia in Post-COVID Era: Increasing incidence of endemic fluconazole-resistant Candida parapsilosis and Candidozyma auris.

Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Published: May 21, 2026

Migration-related inequalities in HIV diagnosis, treatment initiation and retention in care among migrants in Greece.

Migration-related inequalities in HIV diagnosis, treatment initiation and retention in care among migrants in Greece.

Journal: HIV medicine

Published: May 15, 2026

Real-World Data on the Effectiveness and Use of Intravenous Fosfomycin for the Treatment of Difficult-to-Treat Infections Caused by Carbapenem-Resistant Gram-Negative Bacteria-A Subgroup Analysis from the FORTRESS Study.

Real-World Data on the Effectiveness and Use of Intravenous Fosfomycin for the Treatment of Difficult-to-Treat Infections Caused by Carbapenem-Resistant Gram-Negative Bacteria-A Subgroup Analysis from the FORTRESS Study.

Journal: Infectious diseases and therapy

Published: April 23, 2026

Characteristics and management of low-level viraemia in people living with HIV in a resource-limited setting: A multicentre retrospective study in Greece.

Characteristics and management of low-level viraemia in people living with HIV in a resource-limited setting: A multicentre retrospective study in Greece.

Journal: HIV medicine

Published: February 26, 2026

Host restriction factors and p17-Driven inflammaging in HIV-1: From molecular pathogenesis to functional cure.

Host restriction factors and p17-Driven inflammaging in HIV-1: From molecular pathogenesis to functional cure.

Journal: AIMS microbiology

Published: January 26, 2026

Remdesivir: Real-World Effectiveness and Safety in Individuals Hospitalized for Non-COVID Reasons and Non-Hospitalized High-Risk Patients During the Omicron Era in Greece.

Remdesivir: Real-World Effectiveness and Safety in Individuals Hospitalized for Non-COVID Reasons and Non-Hospitalized High-Risk Patients During the Omicron Era in Greece.

Journal: Microorganisms

Published: January 12, 2026

Knowledge and Attitudes of Community Pharmacists Towards Antibiotic Use and Antimicrobial Resistance in Western Greece.

Knowledge and Attitudes of Community Pharmacists Towards Antibiotic Use and Antimicrobial Resistance in Western Greece.

Journal: Antibiotics (Basel, Switzerland)

Published: January 04, 2026

Lipidemic Profile of Patients with Non-Small Cell Lung Cancer and Its Association with Driver Mutations: A Tertiary Center Retrospective Study.

Lipidemic Profile of Patients with Non-Small Cell Lung Cancer and Its Association with Driver Mutations: A Tertiary Center Retrospective Study.

Journal: Cancers

Published: December 18, 2025

Validating pancreatic stone protein for early sepsis detection and outcome prediction in community acquired infections: evidence from a tertiary medical centre.

Validating pancreatic stone protein for early sepsis detection and outcome prediction in community acquired infections: evidence from a tertiary medical centre.

Journal: Infectious diseases (London, England)

Published: December 07, 2025

Dalbavancin for Bone and Joint Infections: A Two-Center Greek Real-World Retrospective Study.

Dalbavancin for Bone and Joint Infections: A Two-Center Greek Real-World Retrospective Study.

Journal: Pathogens (Basel, Switzerland)

Published: October 12, 2025

Showing 1-12 of 181

Last Updated: 09/26/2026